US Market Changes in the Treatment of Advanced Lung Cancer
The purpose of this study is to examine changes in the market for therapeutics used in the treatment of advanced lung cancer by examining longitudinal practice patterns of oncologists. Progressively unfolding patient case scenarios were presented to 152 U.S. oncologists for their responses to open-ended questions concerning their choices of treatment regimens, factors that influence their decisions, barriers to optimal patient treatment and confidence in treatment and management of patients. This report examines the market for therapeutics by comparing oncology practice patterns in the treatment of advanced lung cancer in 2011 and 2012.
CHAPTER 1: INTRODUCTION
CHAPTER 2: RESPONDENT DEMOGRAPHICS
CHAPTER 3: TREATMENT OF A SMOKER WITH SQUAMOUS CELL CARCINOMA
CHAPTER 4: TREATMENT OF A LIGHT SMOKER WITH ADENOCARCINOMA
CHAPTER 5: TREATMENT OF A NEVER-SMOKER WITH ADENOCARCINOMA
CHAPTER 6: TREATMENT OF AN EGFR MUTATION POSITIVE ADENOCARCINOMA
APPENDIX A: SURVEY INSTRUMENT
CHAPTER 2: RESPONDENT DEMOGRAPHICS
CHAPTER 3: TREATMENT OF A SMOKER WITH SQUAMOUS CELL CARCINOMA
CHAPTER 4: TREATMENT OF A LIGHT SMOKER WITH ADENOCARCINOMA
CHAPTER 5: TREATMENT OF A NEVER-SMOKER WITH ADENOCARCINOMA
CHAPTER 6: TREATMENT OF AN EGFR MUTATION POSITIVE ADENOCARCINOMA
APPENDIX A: SURVEY INSTRUMENT
